Nowture Launches Two New Health Companies with an Investment of Four Million

Nowture, from venture capital to venture builder. The Spanish company, an investment ecosystem for biotechnology and life sciences companies, launches two new health companies on the market, which will require a minimum investment of four million euros, according to Mario Grande, co-founder of Nowture.

If you want to read more details about Nowture and find the most important business news of the day, download for free our companion app Born2Invest.

Historically, Nowture has invested in companies in the healthcare and life sciences sector and has offered an accompanying service

Now his model turns to venture building, with which he will promote, specifically and for now, two companies: one specialized in osteoarthritis and the other focused on amyotrophic lateral sclerosis (ALS).

In fact, Nowture has already shaped these companies, which are in the “preclinical approach” plan or phase, according to Grande. The company specializing in osteoarthritis is called Ostherix, while the company that investigates ALS is called Calis.

Nowture wants to consolidate four projects this year

Beyond these consolidated projects, Nowture is working on the creation of two other companies, which will be specialized in cardiology (specifically in the development of drugs against the sequelae of a heart attack) and lung cancer.

Nowture’s idea is to consolidate the four projects this year, although Grande acknowledges that there are currently a total of ten initiatives being evaluated and that 300 cases are studied annually.

Nowture is in charge of accelerating the technological transformation of these companies. Specifically, the company obtains the rights to exploit the patent, that is, it becomes the owner of the intellectual property. “We set up projects that will have an easier time with a buyer in the future,” says Grande, who adds that “Spain is the ninth country in the generation of science around biotechnology and there are few projects that carry out what Nowture does.”

In 2021, Nowture entered into the capital of Libera Bio, a company specialized in applying nanotechnology in the development of cancer therapies

Grande comments that each consolidated project will require an annual investment of two million euros, an amount that can be provided by both Nowture and other investors. The horizon is that these companies receive financing between five and ten years.

Nowture is the new image, since the end of 2020, of the investor until then known as XtartCube. It has financial instruments for an accumulated value of three million euros.

In 2021, Nowture entered into the capital of Libera Bio, a company specializing in applying nanotechnology in the development of cancer therapies to increase efficacy and eliminate the toxicity of current treatments.

Libera Bio is a spin-off from the laboratory of the scientist María José Alonso from the University of Santiago de Compostela  (Galicia). He is developing a series of patents around the Multifunctional Polymeric Nanocapsules (NPM) Technology.

__

(Featured image by moreschy via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.